 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
28 News |  |
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial completion, Trial completion date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 3, 2023
P2, N=15, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Nov 2022
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial termination, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Apr 27, 2023
P2, N=8, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Nov 2022 Unknown status --> Terminated; Primary co-investigator leaving the institution & funding transfer.
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment change, Trial termination, Metastases: Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 23, 2022
P2, N=43, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Unknown status --> Terminated; Primary co-investigator leaving the institution & funding transfer. N=63 --> 43 | Unknown status --> Terminated
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment closed, Enrollment change, Trial completion date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Nov 15, 2022
P2, N=15, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=63 --> 43 | Unknown status --> Terminated Recruiting --> Active, not recruiting | N=33 --> 15 | Trial completion date: Dec 2021 --> Jun 2023
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 1, 2021
P2, N=33, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | N=33 --> 15 | Trial completion date: Dec 2021 --> Jun 2023 Trial completion date: Jan 2021 --> Dec 2021 | Trial primary completion date: Jan 2021 --> Dec 2021
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Dec 17, 2020
P2, N=33, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Jan 2021 --> Dec 2021 | Trial primary completion date: Jan 2021 --> Dec 2021 Trial completion date: Dec 2019 --> Jan 2021 | Trial primary completion date: Dec 2019 --> Jan 2021
- | HER2Bi-armed ATC / TransTarget
Journal, CAR T-Cell Therapy: Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. (Pubmed Central) - Jul 16, 2020
HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2/EGFR/CD19 tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer. (Poster Board D21) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_560;
P2
Clinical trial information: NCT03406858. Research Funding: Merck Inc and NIH Cancer Center Support Grant CA-22453, Pharmaceutical/Biotech Company, U.S. National Institutes of Health.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer. (Poster Board D21) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_257;
P2
Clinical trial information: NCT03406858. Research Funding: Merck Inc and NIH Cancer Center Support Grant CA-22453, Pharmaceutical/Biotech Company, U.S. National Institutes of Health.
- HER2Bi-armed ATC / TransTarget
Superior anti-tumor activity of metabolically enhanced bispecific antibody armed CAR-less Bionic T cells (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_584;
Sequential killing by HER2Bi armed BTC followed by (f/b) EGFRBi armed BTC showed efficient killing against target cells (86.2%) or EGFRBi-BTC f/b HER2Bi-BTC (88.2%) compared to the killing by HER2Bi-BTC (49.7%) or EGFRBi-BTC (43.5%) alone at low E/T ratio in the presence of 100 IU/ml IL-2 at 96 hours... Data show that armed BTC: 1) exhibit superior survival in hypoxic condition; 2) can effectively kill multiple tumor targets in serial killing assay; 3) cytokines and chemokines show immune modulating and tumor killing profile.
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial initiation date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 21, 2018
P2, N=33, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Data show that armed BTC: 1) exhibit superior survival in hypoxic condition; 2) can effectively kill multiple tumor targets in serial killing assay; 3) cytokines and chemokines show immune modulating and tumor killing profile. Initiation date: Feb 2018 --> Jun 2018
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial completion date, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Apr 17, 2018
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Initiation date: Feb 2018 --> Jun 2018 Trial completion date: Jun 2017 --> Dec 2018
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment open, Trial initiation date, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 13, 2018
P2, N=33, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Jun 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
New P2 trial, Checkpoint inhibition, Metastases: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 23, 2018
P2, N=33, Not yet recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer (clinicaltrials.gov) - May 22, 2017
P2, N=63, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018 Trial primary completion date: Jan 2017 --> Jan 2018
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=63, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Aug 2016 --> Jan 2017
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment closed, Enrollment change, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Dec 7, 2016
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Aug 2016 --> Jan 2017 Suspended --> Active, not recruiting | N=32 --> 8
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial primary completion date, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Jul 20, 2016
P2, N=32, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Active, not recruiting | N=32 --> 8 Trial primary completion date: Apr 2016 --> Jun 2017
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial suspension, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Feb 21, 2016
P2, N=32, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Apr 2016 --> Jun 2017 Recruiting --> Suspended
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=63, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Suspended Trial primary completion date: Aug 2015 --> Aug 2016
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Feb 17, 2016
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Aug 2015 --> Aug 2016 N=20 --> 0 | Recruiting --> Withdrawn
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
New P1 trial, IO biomarker: T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System (clinicaltrials.gov) - Jan 25, 2016
P1, N=6, Enrolling by invitation, Sponsor: Yi Miao
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Trial primary completion date, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Aug 24, 2015
P2, N=32, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jun 2015 --> Apr 2016
- | Leukine (sargramostim) / Partner Therap
New P1 trial: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Jun 12, 2015
P1, N=20, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- ||| Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 26, 2015
P2, N=63, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jun 2015 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2015
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment change, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Feb 6, 2015
P2, N=32, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2015 N=48 --> 32
- Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
New P2 trial, Surgery: Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Aug 5, 2012
P2, N=48, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute